Healthcare >> CEO Interviews >> May 13, 2003
MARK LEUCHTENBERGER has been President and Chief Executive
Officer of Therion Biologics Corporation since 2002. He joined
Therion from Biogen, where he served as Vice President,
International. In this capacity, he led all commercial operations
outside of North America. Mr. Leuchtenberger joined Biogen in
1990 and served as Program Executive for Amevive' until assuming
Avonex' program leadership in 1993. In this role, Mr.
Leuchtenberger was responsible for managing the late-stage
development, registration, marketing and North American launch of
Avonex. During his tenure at Biogen, he held several senior
positions, including Vice President of Sales, Marketing and
Business Development where he oversaw the company's global
market, licensing and strategic partnership activities. Prior to
Biogen, he worked as a Senior Consultant at Bain and Company and
specialized in healthcare products and services. Mr.
Leuchtenberger received an MBA from the Yale School of Management
and a BA from Wake Forest University. Profile
Biologics Corporation and where the company is now?
Mr. Leuchtenberger: Therion Biologics Corporation was founded in
1991 to
